A new drug to treat psoriasis has been developed and is in clinical testing. Assume that those individuals given the drug are examined before receiving the treatment and then again after receiving the treatment to determine if there was a change in their symptom status. If the initial results showed that 2.0% of individuals entered the study in remission, 77.0% of individuals entered the study with mild symptoms, 16.0% of individuals entered the study with moderate symptoms, and 5.0% entered the study with severe symptoms calculate and interpret a chi-squared test to determine if the drug was effective treating psoriasis given the information below from the final examination. Remission (No Symptoms of Psoriasis) Mild Symptoms of Psoriasis Moderate Symptoms of Psoriasis Severe Symptoms of Psoriasis Total Number of Participants to Receive the Drug Number of Participants 380 520 95 5 1000 A) We reject H0 because 310.075 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. B) We reject H0 because 310.075 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. C) We reject H0 because 310.075 is greater than 9.49. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. D) We reject H0 because 310.075 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. I am not sure even how to start much less get the answer?

A new drug to treat psoriasis has been developed and is in clinical testing. Assume that those individuals given the drug are examined before receiving the treatment and then again after receiving the treatment to determine if there was a change in their symptom status. If the initial results showed that 2.0% of individuals entered the study in remission, 77.0% of individuals entered the study with mild symptoms, 16.0% of individuals entered the study with moderate symptoms, and 5.0% entered the study with severe symptoms calculate and interpret a chi-squared test to determine if the drug was effective treating psoriasis given the information below from the final examination. Remission (No Symptoms of Psoriasis) Mild Symptoms of Psoriasis Moderate Symptoms of Psoriasis Severe Symptoms of Psoriasis Total Number of Participants to Receive the Drug Number of Participants 380 520 95 5 1000 A) We reject H0 because 310.075 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. B) We reject H0 because 310.075 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. C) We reject H0 because 310.075 is greater than 9.49. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. D) We reject H0 because 310.075 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. I am not sure even how to start much less get the answer?

Holt Mcdougal Larson Pre-algebra: Student Edition 2012

1st Edition

ISBN:9780547587776

Author:HOLT MCDOUGAL

Publisher:HOLT MCDOUGAL

Chapter11: Data Analysis And Probability

Section: Chapter Questions

Problem 8CR

See similar textbooks

Related questions

Question

100%

	Remission (No Symptoms of Psoriasis)	Mild Symptoms of Psoriasis	Moderate Symptoms of Psoriasis	Severe Symptoms of Psoriasis	Total Number of Participants to Receive the Drug
Number of Participants	380	520	95	5	1000

A) We reject H0 because 310.075 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.
B) We reject H0 because 310.075 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.
C) We reject H0 because 310.075 is greater than 9.49. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.
D) We reject H0 because 310.075 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.

I am not sure even how to start much less get the answer?

Expert Solution

Trending now

This is a popular solution!

Step by step

Solved in 4 steps with 2 images

SEE SOLUTION Check out a sample Q&A here

Knowledge Booster

$Research Ethics$

Learn more about

Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, statistics and related others by exploring similar questions and additional content below.